BioAge Labs, Inc. Common Stock (BIOA) Stock
Key stats
- Market cap
- $269.73M
- Price / Earnings ratio
- -2.5x
- EPS (TTM)
- -$2.55
- Volume
- Loading
- 52-week high
- $25.96
- 52-week low
- $4.81
Source: third-party data provider, as of November 13, 2026
Compare with BIOA
Recent news

Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
BIOA

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BIOA

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BIOA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.87
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.43
- MACD histogram
- 0.14
- SMA 50
- $6.76
- Price below SMA 50
- EMA 50
- $7.30
- Price below EMA 50
- SMA 200
- $15.25
- Price below SMA 200
- EMA 200
- $12.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
BIOA

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BIOA

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BIOA

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BIOA

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
BIOA

BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BIOA

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
BIOA

An Airline, Biotechs, and More See Huge Insider Buying
An Airline, Biotechs, and More See Huge Insider Buying
BIOA
News tone: automated (AI) classification of the article's content, not a price prediction.
About BioAge Labs, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 1984 |
| Dr. Eric Morgen M.D. | Co-Founder, COO & Director | 1983 |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer | 1967 |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive VP of Research | 1954 |
| Mr. Shane Barton CPA | Senior Vice President of Finance & Accounting | 1971 |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research | — |
| Ms. Julie Gammelgard | Senior Vice President of People | — |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging | — |
| Mr. BJ Sullivan Ph.D. | Chief Strategy Officer | — |
| Ms. Ann C. Neale RN BSN | Chief Development Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.87
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.43
- MACD histogram
- 0.14
- SMA 50
- $6.76
- Price below SMA 50
- EMA 50
- $7.30
- Price below EMA 50
- SMA 200
- $15.25
- Price below SMA 200
- EMA 200
- $12.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $28.25
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +13.6 | +16.5 | -14.2 | -66.8 | ||||||||
| 2025 | -17.4 | -1.7 | -13.0 | +17.3 | -4.3 | +2.0 | +6.5 | +19.7 | +26.5 | +27.9 | +27.9 | +48.2 |
| 2026 | +48.0 | +10.8 | -19.4 | -5.0 | +3.0 | +42.5 | -62.7 | -11.9 | -25.5 | -13.8 | +1.2 |



